



With considering serum concentration of the uric acid in humans we are observing hyperuricemia and possible gout development. Many epidemi-
ological studies have shown the relationship between the uric acid and diff erent disorders such are obesity, metabolic syndrome, hypertension and 
coronary artery disease. Clinicians and investigators recognized serum uric acid concentration as very important diagnostic and prognostic factor of 
many multifactorial disorders. This review presented few clinical conditions which are not directly related to uric acid, but the concentrations of uric 
acid might have a great impact in observing, monitoring, prognosis and therapy of such disorders. Uric acid is recognized as a marker of oxidative 
stress. Production of the uric acid includes enzyme xanthine oxidase which is involved in producing of radical-oxigen species (ROS). As by-products 
ROS have a signifi cant role in the increased vascular oxidative stress and might be involved in atherogenesis. Uric acid may inhibit endothelial fun-
ction by inhibition of nitric oxide-function under conditions of oxidative stress. Down regulation of nitric oxide and induction of endothelial dysfun-
ction might also be involved in pathogenesis of hypertension. The most important and well evidenced is possible predictive role of uric acid in 
predicting short-term outcome (mortality) in acute myocardial infarction (AMI) patients and stroke. Nephrolithiasis of uric acid origin is signifi cantly 
more common among patients with the metabolic syndrome and obesity. On contrary to this, uric acid also acts is an ‘‘antioxidant’’, a free radical 
scavenger and a chelator of transitional metal ions which are converted to poorly reactive forms.
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Uric acid is a weak organic acid, the end product of 
purine nucleotides degradation (1). Source of pu-
rine nucleotides are ingestion, endogenous syn-
thesis of purines from nonpurine precursors, and 
reutilization of preformed purine compounds (2). 
Degradation of purine nucleotides (Figure 1) starts 
with nucleotidase activity in reaction which releas-
es phosphate from nucleotides and produces nu-
cleosides, adenosine and guanosine (3). Adenosine 
is than deaminated into inosine in reaction cata-
lyzed by adenosine deaminase. Purine nucleotide 
phosphorilase hydrolyses ribose group from inos-
ine and guanosine to produce xypoxantine and 
guanine, respectively (3). Guanine is deaminated 
to xsantine. Xantine oxidoreductase is widely dis-
tributed enzyme. It oxidases hypoxantine to xsan-
tine, and fi nally xantine to uric acid in the liver, gut, 
lung, kidney, heart, brain and plasma (4).
Under the steady-state conditions the production 
of uric acid is in balance with the uric acid disposal 
(5). Deposition of monosodium urate monohy-
drate microcrystals or uric acid in various parts of 
the body leads to the development of gout, com-
mon painful rheumatic disease (6). Gout is not only 
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disorder which might have altered concentrations 
of serum uric acid (SUA). The enzymes involved in 
uric acid production are also responsible for oxida-
tive stress (1) and it was evidenced that SUA might 
be dependently or independently related to diff er-
ent multifactorial disordes. Elevated SUA positively 
correlates with development and progression of 
cardiovascular diseases (7). There is an evidence of 
positive association between SUA and risk of ma-
jor coronary heart disease events. SUA is signifi -
cantly positive correlated with hypertension and 
renal diseases (8). Nephrolithiasis of uric acid ori-
gin, as well as hyperuricemia, is more common 
among patients with the metabolic syndrome 
(MetS) and obesity (9). There is also a controversial 
opinion about prooxidative and antioxidant prop-
erties of uric acid. Uric acid is a powerful free radi-
cal scavenger in humans (10) but it also represents 
a marker for high levels of damaging oxidative 
stress associated with increased xanthine oxidase 
activity (11). Because of all mentioned facts, it is 
reasonable to determinate SUA concentrations in 
diff erent conditions.
Determination of uric acid concentration includes 
phosphotungistic acid methods, uricase methods 
(in wide usage), high-performance liquid chro-
matograpy methods (reference methods) and dry 
chemistry systems (12).
The subject of this review is to present: a) diff erent 
conditions with observed hyperuricemia; b) corre-
lations and causal connections of uric acid and dif-
ferent disorders like cardiovascular and cerebro-
vascular diseases, hypertension and metabolic 
syndrome; c) the protective and pathogenic role 
of uric acid in those conditions; and d) advantage 
for widespread determination of uric acid.
Uric acid precipitation and gout
Gout is common painful rheumatic disease, result-
ing from the deposition of monosodium urate 
monohydrate microcrystals or uric acid in various 
parts of the body, primarily in joints and surround-
ing tissues due to overproduction or underexcre-
tion of poorly soluble uric acid which is the end 
FIGURE 1. Degradation of purine nucleotides and formation of uric acid. 1 - Nucleotidase; 2 - Adenosine deaminase; 3 - Inosine phos-
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product of endogenous and dietary purine me-
tabolism in humans (6). Uric acid ionizes with pKa 
at pH 5.75 (6). In the extracellular fl uid, at physio-
logical pH of 7.4, uric acid is mainly in the ionized 
form of urate, while in the urine, which is usually 
acidic, the un-ionized uric acid form predominates 
(13). Risk for crystal formation and precipitation in-
creases when urate concentrations exceed 380 
μmol/L. Uric acid concentration is controlled by 
synthesis and cell turnover and in the other hand 
by the rate of destruction, excretion and reabsorp-
tion by the kidney. In urine, at pH 5.0, predomi-
nates undissociated uric acid formed from urinary 
urate in the renal tubule. In healthy individuals 
two-thirds of uric acid is excreted by the kidney 
and one-third by the intestine with breakdown of 
urate by gut bacteria. Purine ingestion, endoge-
nous synthesis of purines from nonpurine precur-
sors, and reutilization of preformed purine com-
pounds are the sources of urate production, an 
overall process that under steady-state conditions 
is in balance with the uric acid disposal (2). Human 
and higher primates lack peroxisomal enzyme ura-
te oxidase (uricase) (14) that catalyzes degradation 
of uric acid to more soluble product allantoin that 
is easily eliminated by renal excretion in the most 
other mammals because the genes for uricase 
have mutated and become dysfunctional (15). 
Consequently, serum urate levels in humans are to 
its limit of solubility. Hyperuricaemia is a risk factor 
for gout, but gout can occur where serum uric acid 
levels are low (16). Also, individual can have uric 
acid concentrations above normal and not have 
gout. The prevalence of gout varies with age and 
gender, and is more common in older individuals 
(16). Gout is more common in men than in women, 
but women become increasingly susceptible to 
gout after menopause because of increased urice-
mia parallel with decreasing of estrogen levels (17). 
Risk factors for gout are also obesity, metabolic 
syndrome, diuretic therapy, high-purine diet and 
alcohol intake. Gout can be classifi ed as primary or 
secondary, depending on the presence / absence 
of an identifi ed cause of hyperuricemia. Primary 
gout is more common, without identifi able under-
lying disease causing of the hyperuricemia (18). 
Secondary gout, which is less common, can be a 
result of many conditions (6,19). Alcohol intoxica-
tion causes lactic acidemia and reduces renal urate 
excretion (19). Thiazide and loop diuretics (antihy-
pertensives), increase serum urate levels by inter-
fering with renal tubular ion transport (19). Several 
immunosuppressant like cyclosporine, used in pa-
tients undergoing solid organ transplantation, 
substantially reduces the renal clearance of serum 
urate (19). Malignant diseases are characterized 
with intensive purine metabolism which might 
lead to hyperuricemia and gout. In patient with re-
nal failure, hyperuricemia is, behind the other, one 
of characteristic caused by impaired kidney func-
tion (20). Gout can be the consequence of heredi-
tary interstitial kidney disease, because of renal 
failure which is caused with this hereditary disor-
der (21).
SUA concentration might be decreased by usage 
of a number of pharmacologic agents, dietary and 
other risk factor modifi cations. Gout management 
is very diffi  cult because gout and hyperuricemia 
may have a great impact in some co morbidities, 
but on contrary higher urate levels potentially 
have some benefi cial eff ects (22). Namely, uric acid 
itself may serve as an immune system stimulant, 
urate is a potent antioxidant, it helps to maintain 
blood pressure in a salt-poor environment and it 
implies some benefi ts in several disease of central 
nervous system, probably because of its antioxi-
dant properties (22).
It is also important to defi ne if hyperuricemia and 
gout are either a consequence or a cause of these 
related conditions. The treatment of gout includes 
the changes in lifestyle, nutrition, and adjunctive 
therapies as well as diff erent classes of drugs which 
are approved for lowering urate levels: xanthine 
oxidase inhibitors, uricosuric agents, uricase agents 
and some which are still under development, such 
are inhibitors of urate transporter, purine nucleo-
side phosphorylase and interleukin-1 antagonists 
(23). The safety and effi  cacy of combination thera-
pies for the treatment of gout still remained un-
clear. Unfortunately, lowering of urate concentra-
tion does not relive gout symptoms and urate-
lowering effi  cacy is poor as well as clinical out-
comes in gout patients (24). Hyperuricemia with 
gout, isolated gout without hyperiuricemia or hy-
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peruricemia without gout are conditions which re-
quire ordinarily monitoring. Therapy indications, 
as well as changes in lifestyle, depend also on the 
other risk factors.
Uric acid and oxidative stress
Oxidative stress is considered to be one of the 
main reasons of cells function impairment. It is a 
condition of excessive production of free radicals 
and reactive oxygen species (ROS), as well as re-
duced antioxidative system, due to decreased in-
take of antioxidants or their excessive consump-
tion (25). It is also a condition in which oxido-re-
ductive processes in cells are turned in favor of ox-
idation due to excessive formation of free radicals 
and reactive oxygen species (ROS) (25). Uric acid is 
a product of purine nucleotides catabolism in the 
process catalyzed by liver enzyme xanthine oxi-
doreductase (XOR), which enables the oxidation of 
hypoxanthine to xanthine and its further oxidation 
to uric acid (26). During the production of uric acid 
catalyzed by xsanthine-oxidase, ROS are generat-
ed as by product, which have a signifi cant role in 
the increased vascular oxidative stress (26).
XOR is a hepatic enzyme which catalyzes the pro-
duction of uric acid, nitric oxide, and reactive oxy-
gen species, which potentially damage deoxyribo-
nucleic acid, ribonucleic acid and proteins, inacti-
vate enzymes, oxidize amino acids and convert 
poly-unsaturated fatty acids to lipids (27). XOR ex-
ists in two inter-convertible forms: XO-xantine oxi-
dase and XDH-xanthine dehydrogenase (1,28). Hu-
mane XOR exists in vivo as the dehydrogenase 
form but is easily converted to XO by oxidation of 
the sulfhydryl residues or by proteolysis (4). There 
is the diff erence in substrate affi  nity of XO and XDH 
subforms (Table 1). XDH preferentially reduces 
NAD+, whereas XO cannot reduce NAD+, preferring 
molecular oxygen (28). Reduction of molecular ox-
ygen by either form of the enzyme yields superox-
ide and hydrogen peroxide (1,4,28), Uric acid is rec-
ognized as a marker of oxidative stress, but also as 
a protective factor acting as an antioxidant (10,29).
Regarding XO role in oxidative stress and 
pathophysiology of CVD, most therapeutic ap-
proaches are oriented on inhibiting the XO activity 
and disabling free radicals accumulation as a fea-
sible target. Some studies showed that therapeu-
tic use of allopurinol, xanthine oxidase inhibitor, 
which reduces serum levels of uric acid, show pro-
tective eff ects in situations associated with oxida-
tive stress (27,30), because of decreasing of ROS. In 
clinical studies, for example in coronary bypass 
surgery, the protective eff ects of allopurinol are 
noticed as decreased hospital mortality rate, in-
creased cardiac index, better postoperative recov-
ery and reduced lipid peroxidation (4). In heart fail-
ure allopurinol improves myocardial contractility 
by restoring myocardial calcium sensitivity and 
β-adrenergic responsiveness (31). The other expla-
nation of benefi tial allopurinol eff ect considers the 
eff ects on vascular endothelial function. Xanthine 
oxidase plays a key role in mediating intermittent 
hypoxia-induced vascular dysfunction and admin-
istration of allopurinol might prevent it (32). The 
investigations on animal models in the most cases 
also confi rmed the benefi cial eff ect of allopurinol 
after induction of myocardial infarction (4) with re-
ducing myocardial damage, better recovery of 
ventricular function, better preservation of cellular 
ATP levels and mitochondrial ATP generation dur-
ing ischemia and prevention of the decrease in left 
ventricular pressure. The benefi cial eff ects of al-
lopurinol may be unrelated to the inhibition of the 
XO, and decreasing the free radicals. The eff ects of 
allopurinol action as a xanthine-oxidase inhibitor 
are increasing of intermediates, hypoxanthine and 
Xanthine oxidase (XO) Xanthine dehydrogenase (XDH)
Hypoxanthine + H2O +2O2 →Xanthine + O2-+ H2O2
Xanthine + H2O+2O2→Uric acid + O2-+ H2O2
Hypoxanthine+NAD+ +H2O→Xanthine+ NADH+ H+
Xanthine + NAD++H2O→Uric acid+NADH+ H+
*XDH prefers NAD+ as oxidizing substrate (but it is able to react with O2), while XO uses only O2
TABLE 1. Xanthine oxidoreductase (XOR) isoforms and characteristic reactions (4,28).
Biochemia Medica 2012;22(1):63–75
  67
Pasalic D. et al. Uric acid in multifactorial disorders
xanthine, and decreasing of fi nal product uric-acid 
(33). Taking into account that xanthine derivatives 
are widely used medicaments in treatment of dif-
ferent disease (infl ammatory diseases, behavioral, 
neurodegenerative diseases, renal diseases, respi-
ratory diseases, cancer pain etc, (34) the eff ect of 
xanthine or hypoxhantine should be considered in 
explanations of the mechanisms involved in ef-
fects of XOR inhibition (35). It is well known that 
widely used and examinated xanthine derivative is 
caff eine. The biological eff ects of caff eine and oth-
er xanthines have many molecular targets. Xan-
thines are antagonists of adenosine receptors, in-
hibitors of phosphodiesterases, antagonists of 
GABA receptors and sensibilators of calcium re-
leaseryanodine-sensitive channels in the sarcoplas-
mic and endoplasmic reticulum (34). It appeared that 
caff eine also has stimulatory eff ects on Mg-ATPase 
and calcium sensitivity in cardiac myofi brils (36).
Uric acid itself also can have an impact in oxidative 
stress. Experimental data showed that NO- labeled 
1,3-15N2-uric acid (15N2-UA) under anaerobic condi-
tions in several diff erent media, including human 
plasma and endothelial cell lysates results with 
production of 5-aminouracil (5-AU) and 6-aminou-
racil (6-AU) (37). These fi ndings provide a mecha-
nism for how uric acid may inhibit endothelial 
function by inhibition of NO-function under con-
ditions of oxidative stress (37). Recent clinical stud-
ies demonstrated that high-dose allopurinol usage 
was associated with a lower risk of cardiovascular 
events and all-cause mortality (38), and that pro-
foundly reduces vascular tissue oxidative stress and 
improves vascular/endothelial dysfunction (39).
Elevated serum concentration of uric acid are as-
sociated with increased risk for cardiovascular dis-
ease (CVD) (40), but there are also evidence of their 
potential role as antioxidants in CVD (41). Some 
protective and pathogenic roles of uric acid are 
summarized in table 2. Uric acid acts as an ‘‘anti-
oxidant’’ substance with acting as a free radical 
scavenger and a chelator of transitional metal ions 
which are converted to poorly reactive forms (42). 
Both in vitro and in vivo studies confi rmed that uric 
acid is a powerful free radical scavenger in humans 
(10). Antioxidant properties of uric acid could be 
expected to off er a number of benefi ts within the 
cardiovascular system or other oxidative stress re-
lated disorders. Thus, the role of high uric acid lev-
els (supportive or protective) in development of 
cardiovascular disease is still unclear, and the ex-
planations lie in diff erent approach of in vitro ex-
perimental studies, as well as in diff erent design of 
clinical studies.
The role of uric acid in cardiovascular 
and cerebrovascular disorders
Pathophisiology of atherosclerosis and its conse-
quences coronary artery disease, cererebrovascu-
lar disease and fi nally acute myocardial infarction 
(AMI) and stroke are related to oxidative stress. In-
terrelationship between concentrations of SUA 
and cardiovascular or cerebrovascular diseases has 
been observed for a long time. Most of the cardio-
vascular risk factors are in potentially overlapping 
with SUA concentrations (43-45). The positive as-
sociation of hyperuricemia with obesity, impaired 
glucose tolerance, hypertension and history of 
heart disease was observed on a large Finland co-
hort population (aged 40-69) (43). The study also 
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peruricemic men and women in 5 years than in 
normouricemics (43). Retrospective analysis of 
general Italian population (N = 10,181) showed that 
study subjects with hyperuricemia were character-
ized by signifi cantly higher prevalence of abnor-
mal values of fasting plasma glucose and triglycer-
ides as compared to subjects with reference con-
centrations (45).
The most important and well evidenced is possi-
ble predictive role of uric acid in predicting short-
term outcome (mortality) in AMI patients and 
stroke (43,46).
Diff erent prospective studies exploring the inter-
relationship between serum uric acid and cardio-
vascular outcomes in various categories of sub-
jects are summarized by Strazzullo and Puig (30). 
In general conclusions, in population samples with 
relatively low risk of CVD, SUA is a very weak pre-
dictor of CVD, but it is a signifi cant independent 
predictor among subjects at high or very high risk 
(30). Based on the study design it has been shown 
that hyperuricemia might be independent factor of 
cardiovascular events (46-48) primarily in subject 
groups with high cardiovascular risk (angiographi-
cally proven CHD, congestive heart failure and 
stroke survivors) (30). The fi rst large prospective 
study was established on 83,683 Austrian men co-
hort who was prospectively followed for a median 
of 13.6 years (49). This investigation confi rmed the 
independent relationship between elevated SUA 
and mortality from coronary heart failure and 
stroke, but the association of SUA with mortality 
from acute, subacute, or chronic forms of coronary 
heart disease (CHD) after adjustment for potential 
confounding factors was absent.
Cross-sectional population-based, follow-up study 
of epidemiological data (N = 5926 US-subjects, 
aged 25 to 74) showed that increased serum uric 
acid levels are independently and signifi cantly as-
sociated with risk of cardiovascular mortality (46). 
In cross-sectional study on 982 Turkish patients, 
whom coronary angiography was performed for 
the suspicion of CAD (47), SUA concentrations were 
independently associated with the severity of cor-
onary atherosclerotic plaques. In 212 Spanish pa-
tients, who were hospitalized because of acute HF 
and left ventricular systolic dysfunction, the pres-
ence of hyperuricemia was associated with a high-
er risk of death and/or new hospitalizations in the 
long-term, independently of ventricular function, 
renal function and functional ability (50). Results of 
some other studies, on contrary suggest that se-
rum concentrations of uric acid were not an inde-
pendent risk factor for CVD. In retrospective study, 
which included 716 Korean consecutive patients 
who underwent coronary angiography after ad-
justing for age, diabetes, smoking, cholesterol, and 
metabolic syndrome there were no independent 
association of SUA (51). Any apparent association 
with these outcomes is probably due to the asso-
ciation of uric acid level with other risk factors (52). 
This was shown especially in the studies of general 
population and studies involving patients with his-
tory of arterial hypertension, which didn’t show in-
dependent association with CVD (30). Diff erent in-
vestigations also indicate that uric acid does not 
have a causal role in the development of coronary 
heart disease or death from CVD. The contribution 
of SUA in atherosclerosis development through ef-
fects on arterial calcifi cation was absent in the 
multicentre American Family Heart Study on pop-
ulation-based cohorts in the US, which was de-
signed to assess risk factors for heart disease, the 
association between SUA and carotid atheroscle-
rotic plaques (53). It is evidenced that there is no 
consensus about its action in cardiovascular dis-
ease, although the confi rmation of active partici-
pation of uric acid in heart failure exists (54). How-
ever, investigation based on large prospective 
studies and cross sectional follow-up studies con-
fi rmed the independent association of SUA with 
cardiovascular diseases. On contrary, retrospective 
studies, studies on general population and those 
performed on smaller number of study partici-
pants did not always provided the similar results.
Beside the study design, diff erent observation re-
sults also might be explained on cellular level. 
Namely, there is a diff erence between uric acid in 
serum and intracellular uric acid or highly hydro-
phobic areas such are atherosclerotic plaques and 
adipose tissue. Antioxidant activity is evidenced in 
serum while it seems that intracellular uric acid 
contributes in pathophysiology of heart failure (54).
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It is evidenced from the literature data that these 
controversies are very interesting subject for dis-
cussion between diff erent scientifi c groups (55,56). 
Confl icting conclusions of the diff erent studies are 
the consequence of diff erences in the composi-
tions of the population’s studies (number, treat-
ment, biochemical and clinical data), length of fol-
low up, analysis of the diff erent CAD-risk variables 
and corrections according those variables (49). 
Proctor et al. reported on the association between 
high urate levels and atherosclerosis. They state 
that hyperuricemia might have a protective role 
(antioxidant) or it could be a primary cause (pro-
oxidant) in atherosclerosis (57). Protective role of 
uric acid has been established on animal model. 
Intraperitoneal injection of purine derivatives, caf-
feine or uric acid into male C57BL/6 mice signifi -
cantly increased total glutathione (GSH) levels in 
the hippocampus (58). This study suggests that 
caff eine and uric acid induce neuronal GSH syn-
thesis by promoting cysteine uptake, leading to 
neuroprotection (58). The clinical effi  cacy of uric 
acid as a protective antioxidant is currently under 
investigation in a Phase III trial because it was 
shown that co-administration of uric acid and re-
combinant tissue plasminogen activator provides 
synergistic neuroprotection in experimental 
thromboembolic models and protection of oxida-
tive stress in patients with acute stroke (59,60).
It can be concluded that hyperuricemia is not di-
rectly responsible for vascular injury and increased 
risk for cerebrovascular disease but it simply repre-
sent a surrogate marker for high levels of damag-
ing oxidative stress associated with increased xan-
thine oxidase activity (11). Indeed, hyperuricaemia 
is a signifi cant predictor of disease state and pro-
gression of chronic heart failure (61). The assess-
ment of UA is widely available at low cost, which 
may be an advantage for widespread determina-
tion of this marker. As it is preferably for biomark-
ers to fulfi ll the information for the evaluation of 
disease severity, prognosis and treatment (62) it is 
evidenced that uric acid determination is reason-
able for heart failure. Manzano et al. have devel-
oped a novel risk model for elderly patients with 
heart failure which includes uric acid and left-atrial 
dimension and provide a reliable estimate of death 
or hospital admission rates over a 2-year follow-up 
period (63). This might help to identify higher risk 
patients who may benefi t from more intensive 
treatment.
SUA and hypertension
Hypertension and increased SUA additionally com-
plicate the controversies of uric acid role in cardio-
vascular events and the factors involved in patho-
genesis of atherosclerotic consequences. Many 
clinical studies implicate on causative role of uric 
acid in hypertension (8,64). There are at least two 
aspects of interrelationships between hyperten-
sion and uric acid, molecular mechanisms and 
elimination pathways of urates.
For presentation of the fi rst aspect we have re-
viewed a few clinical trials bellow. Randomized, 
double-blind, placebo-controlled, crossover trial 
involving 30 adolescents who had newly diag-
nosed, essential hypertension and SUA > 360 
µmol/L and who were treated with allopurinol, re-
sulted in reduction of blood pressure (65). Close 
association of new-onset essential hypertension in 
children; suggest that lowering of uric acid can 
lower blood pressure in some patients (66). SUA 
impacts blood pressure in pediatric hemodialysis 
patients, independent of volume, nutritional and 
weight status (67). The study on the Polish patients 
which was performed to evaluate the infl uence of 
allopurinol on blood pressure and aortic compli-
ance in patients with arterial hypertension de-
pending on hypotensive therapy with angiotensin-
converting enzyme inhibitor (ACE-I) or thiazide di-
uretic, showed that allopurinol does not produce 
additional antihypertensive eff ects in patients with 
treated arterial hypertension (68). For understand-
ing the mechanisms of uric acid roles either as a 
predictor or consequence, animal models has 
been investigated. In animal models it has been 
shown that induced mild hyperuricemia may con-
tribute to endothelial dysfunction and reduction 
of nitric oxide (NO) levels (69). Uric acid causes hy-
pertension in a rat model through the activation 
of the renin-angiotensin system, down regulation 
of nitric oxide, and induction of endothelial dys-
function and vascular smooth muscle proliferation 
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(64). Some other studies showed that SUA protects 
against progression of hypertension in spontane-
ously hypertensive rats (70). Similarly to the vascu-
lar injury, understanding of the paradox should be 
pointed to metabolic pathway of uric acid produc-
tion through xantine oxidase (1), as well as the dif-
ferences between acting of uric acid inside the 
cells or in the extracellular milieu (71). We have al-
ready mentioned previously that uric acid acts as 
an antioxidant in extracellular fl uid, while in cellu-
lar matrix exerts prooxidative eff ects (8,54).
It is well known how the impaired kidney function 
is involved in mechanisms of hypertension. The 
elimination of urate also depends on kidney func-
tion. The recent study on a large Korean cohort 
which determinate renal function and SUA levels 
showed that glomerular fi ltration rate negatively 
correlated with blood pressures, uric acid, fasting 
plasma glucose, lipid status and C-reactive protein 
and uric acid was found to be an independent fac-
tor associated with glomerular fi ltration rate (72).
2645 Greece systolic heart failure patients were in-
volved in the Beta-Blocker Evaluation of Survival 
Trial (73). The results showed that hyperuricaemia 
might predict poor outcomes primary as a marker 
of increased xanthine oxidase activity. It confi rmed 
signifi cant association with poor outcomes in heart 
failure patients without chronic kidney disease 
(CKD) but not in those with CKD as a consequence 
of decreased renal excretion of uric acid (73).
Uric acid is primarily excreted via the urine. That 
excretion is dependent on a number of urate trans-
porters, including urate transporter 1 (URAT1), or-
ganic ion transporters (OAT1 and OAT3) and ATP-
dependent urate export transporters (MRP4) (74). 
Urate balance depends on those transporters ac-
tivities. Transporter URAT 1 is responsible for the 
reabsorption of urate, which is normally 90% reab-
sorbed after glomerular fi ltration (75). When we 
are considering the infl uence of uric acid on hy-
pertension it should be pointed to all factors which 
might be involved. Kidney function, functionality 
of the transporters, genetic polymorphisms of the 
transporters, factors of the oxidative stress have to 
be included in evaluation of interrelationships be-
tween hyperuricemia and hypertension. Impaired 
kidney function is responsible for many mecha-
nisms involved in pathogenesis of hypertension, 
so the elevation of SUA might be one of them.
SUA and metabolic syndrome
It is well known that nephrolithiasis of uric acid ori-
gin is signifi cantly more common among patients 
with the MetS, obesity and type 2 diabetes (9). 
Prevalence of metabolic abnormalities in Brazilian 
people with metabolic syndrome was associated 
with concentration of uric acid. After Roux-en-Y 
gastric bypass and consequently weight loss uric 
acid concentration were reduced (76). Lower urine 
pH was associated with an increase in waist cir-
cumference in over than thousand Japanese men 
(77). Waist circumference is a key feature for the 
metabolic syndrome and HOMA-R as an index of 
insulin resistance. Lower urine pH was also associ-
ated with an increase in BMI, and an increase in se-
rum uric acid (77). SUA levels were signifi cantly and 
negatively correlated with HDL-C in Korean males, 
but not in females but SUA levels increased signifi -
cantly with an increasing number of MetS compo-
nents and abdominal obesity in both genders (78). 
Elevated levels of uric acid in obese children, com-
pared with lean subjects, at the prepubertal peri-
od, seems to be an early metabolic alteration that 
is associated with other features of insulin resis-
tance syndrome (79). This might be explain with 
the presence of increased intracellular adenosine 
(uric acid precursor), a derivative of higher AMP 
concentrations due to increased synthesis of fatty 
acid-acyl-CoA in peripheral tissues (79), and the 
authors propose that in early obesity increased 
levels of uric acid are related to elevated plasma 
fatty acids. Molecular base for explanations of the 
interrelationship between hyperuricemia and 
MetS, we might also provide from high dietary car-
bohydrates intake especially for fructose or su-
crose intake. On the other hand the animal model 
experiments showed that fructose feed rats vs. 
glucose feed rats, had higher body weight, blood 
pressure, and concentrations of insulin, uric acid 
and triglycerides (80).
Fructose enters hepatocytes and other cells (hu-
man and animal), where it is completely metabo-
Biochemia Medica 2012;22(1):63–75
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lized by fructokinase with the consumption of ATP, 
without negative regulatory mechanism to pre-
vent the depletion of ATP like is in glucose metab-
olism. Lactic acid and uric acid are than generated 
in the process (81). Lowering of the urine pH is than 
the consequence of the organic acids accumulation. 
Metabolic fates of the fructose in the liver than in-
creases the biosynthesis of endogenous triglycer-
ide, VLDL excretion and LDL overproduction (82).
This also was confi rmed in the clinical studies be-
cause it was shown that the reduction in serum 
uric acid correlated directly with the decrease in 
triglyceride levels (72). Any factor that may increase 
biosynthetic pathway in which ATP is consumed 
and adenilate is produces might be involved in 
overproduction of uric acid.
Severe and mild hyperuricemia have been recog-
nized as an independent risk factor for endothelial 
dysfunction, fl ow-mediated vasodilatation of the 
brachial artery in subjects without MetS, whereas 
only severe hyperuricemia (but not mild hyperuri-
cemia) appeared to exacerbate endothelial dys-
function in similar subjects with MetS in middle-
aged healthy Japanese men (83).
The experiments on mice with targeted disruption 
of endothelial nitric oxide synthase (eNOS) showed 
that mice are hypertensive and insulin resistant. 
We have explained previously that uric acid may 
inhibit endothelial function by inhibition of NO-
function under conditions of oxidative stress (37).
Measurement of uric acid concentration
Uric acid concentration might be measured in se-
rum, plasma, urine (12) and in exhaled breath con-
densate (84). Determination of uric acid concentra-
tion includes phosphotungistic acid methods 
(PTA), uricase methods (in wide usage), high-per-
formance liquid chromatography methods (refer-
ence methods), dry chemistry systems (12) and bi-
osensor methods (85). PTA methods interfere with 
many endogenous and exogenous compounds. 
More specifi c and very low cost (less than 10 euro-
cents per analysis) are enzymatic methods with 
bacterial enzyme uricase, uricase- peroxidase stan-
dard method. Ascorbic acid and bilirubin interfere 
with urate determination, so the use of ascorbat 
oxidase and aminophenason is necessary (12). Up-
to-date biosensor methods can also be used as a 
low-cost alternative to conventional methods (85).
Prior to determination of urate in urine, alkaliniza-
tion of urine might be necessary, because of urate 
crystallize at pH lower than 5.75 (86). It is evidenced 
that uric acid concentrations are signifi cantly asso-
ciated with BMI, gender, glomerular fi ltration rate 
and hypertension (61). Many additional factors, in-
cluding exercise (87), diet, drugs, and state of hy-
dration, may result in transient fl uctuations of uric 
acid levels (86). According to that the reference in-
tervals for uric acid aren’t equable, and there is no 
clear limit for hyperuricemia. So it is very impor-
tant to document well the strategy and the indi-
viduals included in the reference interval (88).
Conclusions
Instead of its controversial role in pathogenesis of 
diff erent disorders, uric acid may play an impor-
tant role in diagnosis, prognostic and therapy 
monitoring. SUA is a good indicator of the oxida-
tive stress which is involved in pathobiochemisty 
of cardiovascular disorders, obesity, impaired glu-
cose tolerance, hypertension and hyperlipidemias 
(Table 3). Hyperuricemia is not directly responsible 
for vascular injury and increased risk for cardiovas-
cular or cerebrovascular disease but simply repre-
sents a surrogate marker for high levels of damag-
ing oxidative stress associated with increased xan-
thine oxidase activity. Indeed, hyperuricaemia is a 
signifi cant predictor of disease state and progres-
sion of chronic heart failure. The assessment of UA 
is widely available at low cost, which may be an 
advantage for widespread determination of this 
marker.
Uric acid is not only recognized as a marker of oxi-
dative stress. It also has a protective role and acts 
an antioxidant which is involved in clinical investi-
gations of therapy for cerebrovascular disorders in 
combination with the anticoagulants.









Usage of specifi c drugs or intoxication (19) - Alcohol reduced renal urate excretion in lactic acidemia;
Several antihypertensives interfere with renal tubular ion transport;
Immunosuppressants (i.e. cyclosporine), reduce renal clearance of 
serum urate.
Renal failure (20) - Impaired kidney function.
Familial juvenile hyperuricemic nephropathy (90) - Mutation of gene for uromodulin.
Autosomal-dominant medullar cystic kidney dis- -
ease (91)
Mutations of genes for polycystins 1 (PC1) and 2 (PC2).
Cardiovascular disorders (8,64,69)
Coronary heart disease• 
Congestive heart failure• 
Stroke• 
Peripheral artery disease• 
Endothelial dysfunction, oxidative stress, inhibition of NO-synthesis.
Hypertension (8,64,69,72,89) Endothelial disfunction (60);
Activation of renin-angiotensin system (55);
Impaired glomerular fi ltration rate (63);
Inhibition of NO-synthesis.
Chronic kidney disease (8) Increased monocyte chemoattractant protein (MCP-1) in cultured 
vascular smooth muscle cells and human proximal tubular epithelial 
cells.





Increased intracellular adenosine (uric acid precursor a derivative 
of higher AMP concentrations due to increased synthesis of fatty 
acid-acyl-CoA in peripheral tissues. 
Therapy of cancer Purine derivatives
TABLE 3. Disorders and mechanisms involved in hyperuricemia.
References
 1. George J, Struthers AD. Role of urate, xanthine oxidase and 
the eff ects of allopurinol in vascular oxidative stress. Vasc 
Health Risk Manag 2009;5:265-72.
 2. Benedict JD, Forsham PH, Stetten D, Jr. The metabolism of 
uric acid in the normal and gouty human studied with the 
aid of isotopic uric acid. J Biol Chem 1949;181:183-93.
 3. Rodwell VW. Metabolism of purine and pyrimidine nucle-
otides. In: Murray RK, Bender DA, Botham KM, Kennelly PJ, 
Rodwell VW, Weil PA, eds. Harper’s Illustrated Biochemistry. 
New York: McGraw Hill; 2009. p. 292-301.
 4. Pacher P, Nivorozhkin A, Szabo C. Therapeutic eff ects of xan-
thine oxidase inhibitors: renaissance half a century after the 
discovery of allopurinol. Pharmacol Rev 2006;58:87-114.
 5. Chilappa CS, Aronow WS, Shapiro D, Sperber K, Patel U, Ash 
JY. Gout and hyperuricemia. Compr Ther 2010;36:3-13.
 6. Halabe, A, Sperling O. Uric acid nephrolithiasis. Miner Elec-
trolyte Metab 1994;20:424-31.
 7. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric 
acid and cardiovascular disease: recent developments, and 
where do they leave us? Am J Med 2005;118:816-26.
 8. Kanbay M, Solak Y, Dogan E, Lanaspa MA, Covic A. Uric 
acid in hypertension and renal disease: the chicken or the 
egg? Blood Purif 2010;30:288-95.
 9. Maalouf NM. Metabolic syndrome and the genesis of uric 
acid stones. J Ren Nutr 2011;21:128-31.
10. Waring WS. Uric acid: an important antioxidant in acute is-
chaemic stroke. Q J Med 2002;95:691-3.
11. Ferguson LD, Walters MR. Xanthine oxidase inhibition for 
the treatment of stroke disease: a novel therapeutic appro-
ach Expert Rev Cardiovasc Ther 2011;9:399-401.
12. Newman DJ, Price CP. Nonprotein Nitrogen Metabolites. In: 
Burtis CA, Ashwood ER. Eds. Tietz Fundamentals of Clinical 
Chemistry. Philadelphia: Saunders; 2001. p.414-26.
Biochemia Medica 2012;22(1):63–75
  73
Pasalic D. et al. Uric acid in multifactorial disorders
13. Terkeltaub R, Bushinsky DA, Becker MA. Recent develo-
pments in our understanding of the renal basis of hyperuri-
cemia and the development of novel antihyperuricemic the-
rapeutics. Arthritis Research & Therapy 2006;8 Suppl 1:S4.
14. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan 
H, et al. Uric acid, hominoid evolution, and the pathogene-
sis of salt-sensitivity. Hypertension 2002;40:355-60.
15. Wu XW, Lee CC, Muzny DM, Caskey CT. Urate oxidase: pri-
mary structure and evolutionary implications. Proc Natl 
Acad Sci USA 1989;86:9412-6.
16. Liebman SE, Taylor JG, Bushinsky DA. Uric Acid Nephrolithi-
asis. Curr Rheumatol Rep 2007;9:251-7.
17. Hak AE, Choi HK. Menopause, postmenopausal hormone 
use and serum uric acid levels in US women – the Third Na-
tional Health and Nutrition Examination Survey. Arthritis 
Res Ther 2008;10:R116.
18. Richette P, Bardin T. Gout. Lancet 2010;375:318-28.
19. Schlesinger N. Diagnosis of Gout: Clinical, Laboratory, 
and Radiologic fi ndings. Am J Manag Care 2005;11(15 
Suppl):S443-50; quiz S465-8.
20. Gomis Couto A, Teruel Briones JL, Fernández Lucas M, Rive-
ra Gorrin M, Rodríguez Mendiola N, Jiménez Álvaro S, Que-
reda Rodríguez-Navarro C. Causes of unplanned hemodi-
alysis initiation. Nefrologia 2011;31:733-7.
21. Bleyer AJ. Improving the recognition of hereditary interstiti-
al kidney disease. J Am Soc Nephrol 2009;20:11-3.
22. Pillinger MH, Goldfarb DS, Keenan RT. Gout and its comor-
bidities. Bull NYU Hosp Jt Dis 2010;68:199-203.
23. Neogi T. Clinical practice. Gout. N Engl J Med 2011;364:443-52.
24. Becker MA, Schumacher HR, Espinoza LR, Wells AF, Mac-
Donald P, Lloyd E, Lademacher C. The urate-lowering effi  -
cacy and safety of febuxostat in the treatment of the hype-
ruricemia of gout: the CONFIRMS trial. Arthritis Res Ther 
2010;12:R63.
25. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. 
Nat Rev Cancer 2003;3:276-85.
26. Schulz E, Gori T, Münzel T. Oxidative stress and endothelial 
dysfunction in hypertension. Hypertens Res 2011;34:665-73.
27. Riegersperger M, Covic A, Goldsmith D. Allopurinol, uric 
acid, and oxidative stress in cardiorenal disease. Int Urol 
Nephrol 2011;43:441-9.
28. Harrison R. Structure and function of xanthine oxidoreducta-
se: where are we now? Free Radic Biol Med 2002;33:774-97.
29. Nabipour I, Sambrook PN, Blyth FM, Janu MR, Waite LM, 
Naganathan V, et al. Serum uric acid is associated with 
bone health in older men: A cross-sectional population-ba-
sed study. J Bone Miner Res 2011;26:955-64.
30. Strazzullo P, Puig JG. Uric acid and oxidative stress: relative 
impact on cardiovascular risk? Nutr Metab Cardiovasc Dis 
2007;17:409-14.
31. Saliaris AP, Amado LC, Minhas KM, Schuleri KH, Lehrke S, 
St John M, et al. Chronic allopurinol administration ame-
liorates maladaptive alterations in Ca2+ cycling proteins 
and β-adrenergic hyporesponsiveness in heart failure. Am 
J Physiol Heart Circ Physiol 2007;292:H1328-35.
32. Dopp JM, Philippi NR, Marcus NJ, Olson EB, Bird CE, Moran 
JJ, et al. Xanthine Oxidase Inhibition Attenuates Endotheli-
al Dysfunction Caused by Chronic Intermittent Hypoxia in 
Rats. Respiration 2011;82:458-67.
33. Yamazaki I, Soma T, Ichikawa Y, Iwai Y, Kondo J, Matsumo-
to A. Usefulness of allopurinol for prevention of myocardi-
al reperfusion injury in open heart surgery. Nippon Kyobu 
Geka Gakkai Zasshi 1995;43:26-31.
34. Daly JW. Caff eine analogs: biomedical impact. Cell Mol Life 
Sci 2007;64:2153-69.
35. Szentmiklósi AJ, Cseppentō A, Gesztelyi R, Zsuga J, Körtvély 
A, Harmati G, Nánási PP. Xanthine derivatives in the heart: 
blessed or cursed? Curr Med Chem 2011;18:3695-706.
36. Okafor C, Liao R, Perreault-Micale C, Li X, Ito T, Stepanek A, 
et al. Mg-ATPase and Ca2+ activated myosin ATPase acti-
vity in ventricular myofi brils from non-failing and disea-
sed human hearts – eff ects of calcium sensitizing agents 
MCI-154, DPI 201 – 106, and caff eine. Mol Cell Biochem 
2003;245:77-89.
37. Gersch C, Palii SP, Kim KM, Angerhofer A, Johnson RJ, Hen-
derson GN. Inactivation of nitric oxide by uric acid. Nucleo-
sides Nucleotides Nucleic Acids. 2008;27:967-78.
38. Wei L, Mackenzie IS, Chen Y, Struthers AD, MacDonald TM. 
Impact of allopurinol use on urate concentration and car-
diovascular outcome. Br J Clin Pharmacol 2011;71:600-7.
39. Rajendra NS, Ireland S, George J, Belch JJ, Lang CC, Strut-
hers AD. Mechanistic insights into the therapeutic use of 
high-dose allopurinol in angina pectoris.J Am Coll Cardiol 
2011;58:820-8.
40. Bergamini C, Cicoira M, Rossi A, Vassanelli C. Oxidative stre-
ss and hyperuricaemia: pathophysiology, clinical relevan-
ce, and therapeutic implications in chronic heart failure. 
Eur J Heart Fail 2009;11:444-52.
41. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. 
Uric acid and serum antioxidant capacity: a reaction to at-
herosclerosis? Atherosclerosis 2000;148:131-9.
42. Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA. 
Uric acid and oxidative stress. Curr Pharm Des 2005;11: 
4145e51.
43. Reunanen A, Takkunen H, Knekt P, Aromaa A. Hyperurice-
mia as a risk factor for cardiovascular mortality. Acta Med 
Scand Suppl 1982;668:49-59.
44. Bonora E, Targher G, Zenere MB, Saggiani F, Cacciatori V, 
Tosi F, et al. Relationship of uric acid concentration to car-
diovascular risk factors in young men. Role of obesity and 
central fat distribution. The Verona Young Men Atherosc-
lerosis Risk Factors Study. Int J Obes Relat Metab Disord 
1996;20:975-80.
45. Lippi G. Relationship between uric acid, hyperglycemia and 
hypertriglyceridemia in general population. Biochem Med 
2008;18:37-41.
46. Fang J, Alderman MH. Serum uric acid and cardiovascu-
lar mortality the NHANES I epidemiologic follow-up study, 




Pasalic D. et al. Uric acid in multifactorial disorders
47. Kaya EB, Yorgun H, Canpolat U, Hazırolan T, Sunman H, Ül-
gen A, Ates AH, et al. Serum uric acid levels predict the se-
verity and morphology of coronary atherosclerosis detec-
ted by multidetector computed tomography. Atherosclero-
sis 2010;213:178-83.
48. Krishnan E, Pandya BJ, Chung L, Dabbous O. Hyperurice-
mia and the risk for subclinical coronary atherosclerosis - 
data from a prospective observational cohort study. Arthri-
tis Res Ther 2011;13:R66.
49. Strasak A, Ruttmann E, Brant L, Kelleher C, Klenk J, Concin 
H, et al. Serum Uric Acid and Risk of Cardiovascular Morta-
lity: A Prospective Long-Term Study of 83 683 Austrian Men. 
Clin Chem 2008;54:273-84.
50. Pascual-Figal DA, Hurtado-Martínez JA, Redondo B, Anto-
linos MJ, Ruiperez JA, Valdes M. Hyperuricaemia and long-
term outcome after hospital discharge in acute heart failu-
re patients. Eur J Heart Fail 2007;9:518-24.
51. Lim HE, Kim SH, Kim EJ, Kim JW, Rha SW, Seo HS, Park CG. 
Clinical value of serum uric Acid in patients with suspected 
coronary artery disease. Korean J Intern Med 2010;25:21-6.
52. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid 
and risk for cardiovascular disease and death: the Framin-
gham Heart Study. Ann Intern Med 1999;131:7-13.
53. Neogi T, Terkeltaub R, Ellison RC, Hunt S, Zhang Y. Serum 
Urate Is Not Associated with Coronary Artery Calcifi cation: 
The NHLBI Family Heart Study. J Rheumatol 2011;38:111-7.
54. Alcaíno H, Greig D, Castro P, Verdejo H, Mellado R, García 
L, et al. The role of uric acid in heart failure. Rev Med Chile 
2011;139:505-15.
55. Proctor PH. Uric Acid and Neuroprotection. Stroke 2008;39: 
e126.
56. Dawson J, Quinn TJ, Walters MR. Response to Letter by 
Proctor. Stroke 2008;39:e89.
57. Proctor PH. Uric acid: neuroprotective or neurotoxic? Stro-
ke. 2008;39:e88.
58. Aoyama K, Matsumura N, Watabe M, Wang F, Kikuchi-Utsumi 
K, Nakaki T. Caff eine and uric acid mediate glutathione synt-
hesis for neuroprotection. Neuroscience 2011;181:206-15.
59. Amaro S, Planas AM, Chamorro A. Uric acid administration 
in patients with acute stroke: a novel approach to neuropro-
tection. Expert Review of Neurotherapeutics 2008;8:259-70.
60. Amaro S, Chamorro A. Translational stroke research of the 
combination of thrombolysis and antioxidant therapy. 
Stroke 2011;42:1495-9.
61. Doehner W, von Haehling S, Anker SD. Uric acid as a pro-
gnostic marker in acute heart failure—new expectations 
from an old molecule. Eur J Heart Fail 2007;9:437-9.
62. Gruson D, Ahn SA, Rousseau MF. Biomarkers of infl ammati-
on and cardiac remodeling: the quest of relevant compani-
ons for the risk stratifi cation of heart failure patients is still 
ongoing. Biochem Med 2011;21:254-63.
63. Manzano L, Babalis D, Roughton M, Shibata M, Anker SD, 
Ghio S, et al.; SENIORS Investigators. Predictors of clinical 
outcomes in elderly patients with heart failure. Eur J Heart 
Fail 2011;13:528-36.
64. Feig DI, Kang DH, Nakagawa T, Mazzali M, Johnson RJ. Uric 
acid and hypertension. Curr Hypertens Rep 2006;8:111-5.
65. Feig DI, Soletsky B, Johnson RJ. Eff ect of allopurinol on blo-
od pressure of adolescents with newly diagnosed essential 
hypertension: a randomized trial. JAMA. 2008;300:924-32.
66. Feig DI, Johnson RJ. The role of uric acid in pediatric hyper-
tension. J Ren Nutr 2007;17:79-83.
67. Silverstein DM, Srivaths PR, Mattison P, Upadhyay K, Mid-
gley L, Moudgil A, et al. Serum uric acid is associated with 
high blood pressure in pediatric hemodialysis patients. Pe-
diatr Nephrol 2011;26:1123-8.
68. Kostka-Jeziorny K, Uruski P, Tykarski A. Eff ect of allopurinol 
on blood pressure and aortic compliance in hypertensive 
patients. Blood Press 2011;20:104-10.
69. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu 
W, et al. Hyperuricemia induces endothelial dysfunction. 
Kidney Int 2005;67:1739-42.
70. Durante P, Chávez M, Pérez M, Romero F, Rivera F. Eff ect of 
uric acid on hypertension progression in spontaneously 
hypertensive rats. Life Sci 2010;86:957-64.
71. Sautin YY, Nakagawa T, Zharikov S, Johnson. Adverse ef-
fects of the classic antioxidant uric acid in adipocytes: 
ADPH oxidase mediated oxidative/nitrosative stress. Am J 
Physiol Cell Physiol 2007;93:C584-96.
72. Jung DH, Lee YJ, Lee HR, Lee JH, Shim JY. Association of renal 
manifestations with serum uric acid in Korean adults with 
normal uric acid levels. J Korean Med Sci 2010;25:1766-70.
73. Filippatos GS, Ahmed MI, Gladden JD, Mujib M, Aban IB, 
Love TE, et al. Hyperuricaemia, chronic kidney disease, and 
outcomes in heart failure: potential mechanistic insights 
from epidemiological data. Eur Heart J 2011;32:712-20.
74. Kutzing MK, Firestein BL. Altered uric acid levels and disea-
se states. J Pharmacol Exp Ther 2008;324:1-7.
75. Anzai N, Kanai Y, Endou H. New insights into renal tran-
sport of urate. Curr Opin Rheumatol 2007;19:151-7.
76. Serpa Neto A, Rossi FM, Valle LG, Teixeira GK, Rossi M. Rela-
tion of uric acid with components of metabolic syndrome 
before and after Roux-en-Y gastric bypass in morbidly obe-
se subjects. Arq Bras Endocrinol Metabol 2011;55:38-45.
77. Otsuki M, Kitamura T, Goya K, Saito H, Mukai M, Kasayama 
S, et al. Association of urine acidifi cation with visceral obe-
sity and the metabolic syndrome. Endocr J 2011;58:363-7.
78. Lim JH, Kim YK, Kim YS, Na SH, Rhee MY, Lee MM. Relation-
ship between serum uric Acid levels, metabolic syndrome, 
and arterial stiff ness in korean. Korean Circ J 2010;40:314-
20.
79. Gil-Campos M, Aguilera CM, Cañete R, Gil A. Uric acid 
is associated with features of insulin resistance syndro-
me in obese children at prepubertal stage. Nutr Hosp 
2009;24:607-13.
80. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glus-
hakova O, et al. A causal role for uric acid in fructose-in-
duced metabolic syndrome. Am J Physiol Renal Physiol 
2006;290:F625-31.
81. Johnson R J, Segal MS, Sautin Y, Nakagawa T, Feig DI, Kang 
D-H, et al. Potential role of sugar (fructose) in the epidemic 
of hypertension,obesity and the metabolic syndrome, dia-




Pasalic D. et al. Uric acid in multifactorial disorders
82. Lê KA, Tappy L. Metabolic eff ects of fructose. Curr Opin Clin 
Nutr Metab Care 2006;9:469-75.
83. Tomiyama H, Higashi Y, Takase B, Node K, Sata M, Ino-
ue T, et al. Relationships Among Hyperuricemia, Metabo-
lic Syndrome, and Endothelial Function. Am J Hypertens 
2011;24:770-4.
84. Vlasic V, Trifunovic J, Cepelak I, Nimac P, Zrinski Topic R, Do-
dig S. Urates in exhaled breath condensate of children with 
obstructive sleep apnea. Biochem Med 2011;21:139-44.
85. Ballesta-Claver J, Díaz Ortega IF, Valencia-Mirón MC, Ca-
pitán-Vallvey LF. Disposable luminol copolymer-ba-
sed biosensor for uric acid in urine. Anal Chim Acta 
2011;702:254-6.
86. Barr WG. Uric Acid. Editors In: Walker HK, Hall WD, Hurst JW, 
editors. Source Clinical Methods: The History, Physical, and 
Laboratory Examinations. 3rd edition. Boston: Butterwort-
hs; 1990. Chapter 165.
87. Nishida Y, Iyadomi M, Higaki Y, Tanaka H, Hara M, Tanaka 
K. Infl uence of physical activity intensity and aerobic fi tness 
on the anthropometric index and serum uric acid concen-
tration in people with obesity. Intern Med 2011;50:2121-8.
88. Guidi CG, Salvagno GL. Reference intervals as a tool for to-
tal quality management. Biochem Med 2010;20:165-72.
89. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrecti-
on of uric acid as a causal risk factor in essential hyperten-
sion Hypertension 2005;45:18-20.
90. Dahan K, Devuyst O, Smaers M, Vertommen D, Loute G, 
Poux JM, et al. A cluster of mutations in the UMOD gene 
causes familial juvenile hyperuricemic nephropathy with 
abnormal expression of uromodulin. J Am Soc Nephrol 
2003;14:2883–93.
91. Dedoussis GV, Luo Y, Starremans P, Rossetti S, Ramos AJ, 
Cantiello HF, et al. Co-inheritance of a PKD1 mutation and 
homozygous PKD2 variant: a potential modifi er in autoso-
mal dominant polycystic kidney disease. Eur J Clin Invest 
2008;38:180-90.
Mokraćna kiselina kao važan čimbenik multifaktorijelnih poremećaja – 
činjenice i kontroverze
Sažetak
Određujući koncentraciju mokraćne kiseline u serumu kod humanih uzoraka možemo primijetiti hiperuricemiju i moguć razvoj gihta. Mnoga su 
epidemiološka istraživanja pokazala povezanost između mokraćne kiseline i različitih poremećaja kao što su pretilost, metabolički sindrom, po-
višeni tlak i koronarna arterijska bolest. Kliničari i znanstvenici prepoznali su koncentraciju mokraćne kiseline u serumu kao važan dijagnostički 
i prognostički čimbenik mnogih multifaktorijelnih poremećaja. Ovaj pregled predstavlja nekoliko kliničkih stanja koja nisu izravno povezana s 
mokraćnom kiselinom, no na čije promatranje, praćenje, prognostiku i dijagnostiku određivanje koncentracije mokraćne kiseline može imati 
velik utjecaj. Mokraćna kiselina prepoznata je kao biljeg oksidativnog stresa. U stvaranje mokraćne kiseline uključen je enzim ksantin-oksidaza 
koji je prisutan i pri stvaranju reaktivnih kisikovih spojeva (engl. radical-oxigen species, ROS). Kao nusproizvodi, ROS imaju značajnu ulogu kod 
povišenog rizika od vaskularnog oksidacijskog stresa te su možda uključeni i u aterogenezu. Mokraćna bi kiselina mogla inhibirati endotelnu 
funkciju inhibirajući funkciju dušikovog oksida kod oksidativnog stresa. Moguće je da inhibicija dušikovog oksida i indukcija endotelne disfunkcije 
sudjeluju u patogenezi hipertenzije. Najvažnija i potkrijepljena s dovoljno dokaza je potencijalna prediktivna uloga mokraćne kiseline pri predvi-
đanju kratkotrajnih ishoda (smrtnost) kod bolesnika nakon akutnog infarkta miokarda i moždanog udara. Nefrolitijaza uzrokovana mokraćnom 
kiselinom češće se pojavljuje među bolesnicima s metaboličkim sindromom i pretilošću. Suprotno tome mokraćna kiselina također djeluje kao 
antioksidans, čistač slobodnih radikala i kao kelator iona tranzicijskih metala koji prelaze u slabo reaktivne oblike.
Ključne riječi: ateroskleroza; hipertenzija; hiperuricemija; metabolički sindrom; mokraćna kiselina
